<DOC>
	<DOC>NCT01263925</DOC>
	<brief_summary>Investigate, under outpatient conditions, both the effect of 4 weeks of daily treatment with Prostaglandin E1 and that of 4 weeks of interval treatment (two infusions per week) on the pain-free walking distance in patients with Intermittent Claudication.</brief_summary>
	<brief_title>Prostaglandin E1 in Outpatients With Intermittent Claudication</brief_title>
	<detailed_description />
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Alprostadil</mesh_term>
	<criteria>Subjects with Peripheral Arterial Occlusive Disease (PAOD) of the lower extremity in Fontaine stage II Maximum walking distance on the treadmill (12 %, 3 km/h) between 30 and 150 m Stable Intermittent Claudication of at least 6 months standing with no acute shortening of walking distance over the past 3 months Stenoses or occlusions below the Femoral Bifurcation (aboveknee or belowknee type) confirmed by duplex US or angiography Ankle/brachial index ≤ 0.90 with a decrease in systolic ankle pressure of ≥ 10 % after maximum loading (maximum walking distance on the treadmill at 3 km/h, 12 %) The patient is physically and mentally capable of participating in the trial Patient age &gt; 40 years, male and female Patient is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent Patient is willing and able to comply with all trial requirements Surgical or other interventional measures performed on the affected extremity and Prostaglandin treatment within the 6 months immediately prior to the trial Rest pain and Necroses Systolic ankle pressure less than 50 mmHg Change in maximum walking distance during the oneweek Runin Phase of more than ± 25 % of Baseline Successful physical walking training within the 6 months immediately prior to the trial Inflammatory vascular diseases Polyneuropathy in Diabetes Mellitus Diseases limiting walking distance (Arthrosis, inflammatory diseases of the joints, neurological disease, diseases of the Vertebral Column, cardiopulmonary diseases) History of Pulmonary Oedema Myocardial infarction within the past 6 months Pregnancy or nursing Known hypersensitivity to any components of the trial medication or comparative drug Renal insufficiency, compensated retention (creatinine &gt; 2.0 mg/dL) Severe retinal Haemorrhage Massive Haemorrhage Known existing malignant diseases Vasoactive concomitant medication (e.g. Naftidrofuryl, Pentoxifylline, Buflomedil, Cilostazol), or other Prostaglandins Untreated or uncontrolled Hypertension (systolic blood pressure ≥ 180 mmHg, diastolic blood pressure ≥ 110 mmHg) Previous participation of the patient in the present trial Participation of the patient in a trial with the same objectives within the past 6 months, or is currently participating in another trial Illness of the patient due to alcohol or drugabuse within the past 6 months Serious illness of the patient that the investigator considers to compromise his/her participation in the trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Alprostadil</keyword>
	<keyword>Prostaglandin E1</keyword>
	<keyword>Prostavasin®</keyword>
	<keyword>PAOD</keyword>
</DOC>